X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://pharmaphorum.com/news/astellas-generic-myrbetriq-defence-knocked-back-again
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215948
https://endpts.com/astellas-loses-patent-infringement-case-over-blockbuster-bladder-drug/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215948
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209485
https://www.fda.gov/news-events/press-announcements/fda-approves-new-indication-drug-treat-neurogenic-detrusor-overactivity-pediatric-patients
https://www.prnewswire.com/news-releases/fda-accepts-for-priority-review-the-new-drug-application-for-mirabegron-for-oral-suspension-and-supplemental-new-drug-application-for-myrbetriq-mirabegron-tablets-in-pediatric-patients-301201635.html
https://www.fiercebiotech.com/biotech/as-urovant-preps-to-launch-myrbetriq-rival-it-s-all-systems-go-r-d
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209446
https://www.pharmacompass.com/pdf/news/union-quimico-farmaceutica-fails-edqm-inspection-1572404101.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209485
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209488
https://www.moneycontrol.com/news/business/stocks/cadila-healthcare-gains-on-usfdas-tentative-approval-to-market-a-drug-3745691.html
https://endpts.com/vivek-ramaswamys-urovant-claims-a-big-win-in-phiii-but-questions-linger-about-the-cheap-generic-comparator/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209413
https://www.nasdaq.com/article/overactive-bladder-biotech-urovant-sciences-sets-terms-for-150-million-ipo-cm1023564
https://www.prnewswire.com/news-releases/astellas-announces-launch-of-whats-next-sweepstakes-with-laila-ali-300711298.html
https://www.fiercebiotech.com/biotech/urovant-seeks-150m-ipo-just-a-year-after-launch
https://www.prnewswire.com/news-releases/fda-approves-supplemental-new-drug-application-for-myrbetriq-mirabegron-for-use-in-combination-with-solifenacin-succinate-for-the-treatment-of-overactive-bladder-symptoms-300644079.html
https://www.fiercebiotech.com/biotech/urovant-starts-pursuit-astellas-overactive-bladder-drug-myrbetriq-new-ph3-trial
http://www.prnewswire.com/news-releases/us-fda-accepts-for-review-astellas-supplemental-new-drug-application-for-mirabegron-for-use-in-combination-with-solifenacin-succinate-5-mg-for-the-treatment-of-overactive-bladder-300518426.html
http://www.fiercepharma.com/marketing/astellas-new-partner-former-dwts-contender-lea-thompson-myrbetriq-promo
http://www.prnewswire.com/news-releases/astellas-submits-supplemental-new-drug-application-for-mirabegron-for-use-in-combination-with-solifenacin-succinate-5-mg-for-the-treatment-of-overactive-bladder-300482309.html
http://www.pharmatimes.com/news/astellas_and_gedeon_named_for_abpi_code_breaches_1195055
Market Place
Share 
